A086900 logo

Medy-Tox Inc. Stock Price

KOSDAQ:A086900 Community·₩832.5b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A086900 Share Price Performance

₩118,600.00
-68700.00 (-36.68%)
₩118,600.00
-68700.00 (-36.68%)
Price ₩118,600.00

A086900 Community Narratives

There are no narratives available yet.

Recent A086900 News & Updates

Revenues Working Against Medy-Tox Inc.'s (KOSDAQ:086900) Share Price Following 26% Dive

Aug 12
Revenues Working Against Medy-Tox Inc.'s (KOSDAQ:086900) Share Price Following 26% Dive

Here's Why Medy-Tox (KOSDAQ:086900) Can Manage Its Debt Responsibly

May 16
Here's Why Medy-Tox (KOSDAQ:086900) Can Manage Its Debt Responsibly

Investors Appear Satisfied With Medy-Tox Inc.'s (KOSDAQ:086900) Prospects As Shares Rocket 26%

Apr 24
Investors Appear Satisfied With Medy-Tox Inc.'s (KOSDAQ:086900) Prospects As Shares Rocket 26%

We Think Medy-Tox's (KOSDAQ:086900) Robust Earnings Are Conservative

Mar 30
We Think Medy-Tox's (KOSDAQ:086900) Robust Earnings Are Conservative

Lacklustre Performance Is Driving Medy-Tox Inc.'s (KOSDAQ:086900) 27% Price Drop

Nov 18
Lacklustre Performance Is Driving Medy-Tox Inc.'s (KOSDAQ:086900) 27% Price Drop

Medy-Tox Inc. Key Details

₩234.6b

Revenue

₩99.8b

Cost of Revenue

₩134.8b

Gross Profit

₩116.6b

Other Expenses

₩18.2b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
2.60k
Gross Margin
57.45%
Net Profit Margin
7.76%
Debt/Equity Ratio
16.0%

Medy-Tox Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

1 Risk
3 Rewards

About A086900

Founded
2000
Employees
705
CEO
Hyun-Ho Jung
WebsiteView website
www.medytox.com

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

South Korean Market Performance

  • 7 Days: -0.006%
  • 3 Months: 11.7%
  • 1 Year: 32.9%
  • Year to Date: 44.6%
The market has been flat over the last week. More promisingly, the market is up 33% over the past year. Looking forward, earnings are forecast to grow by 24% annually. Market details ›